Pourya Gholizadeh | Immunology and Microbiology | Editorial Board Member

Published on by Academic Excellence

Editorial Board Member

Pourya Gholizadeh
Ardabil University of Medical Sciences,Iran

Pourya Gholizadeh
Affiliation Ardabil University of Medical Sciences
Country Iran
Google Scholar ID 1XSHxVkAAAAJ
Documents 110
Citations 4,556
h-index 37
Subject area Immunology and Microbiology
Event International Academic Excellence Awards

Pourya Gholizadeh is a researcher whose listed publications address antimicrobial resistance, microbial pathogenesis, oral microbiology, and the interactions between microorganisms and human health. His work, as represented by the publications supplied for this profile, connects microbiological mechanisms with clinically relevant questions, including antibiotic resistance and the potential contribution of oral bacteria to disease. This article summarizes selected research themes and publications and presents a profile for academic recognition through the International Academic Excellence Awards. The bibliographic details and research metrics should be checked against their original databases before formal publication.[1]

Abstract

This profile reviews selected research by Pourya Gholizadeh in immunology and microbiology. The supplied publication list highlights antibiotic resistance, the CRISPR-Cas system, oral microbial communities, and bacterial contributions to disease. These topics are relevant to infection prevention, antimicrobial stewardship, and the development of future research strategies. The profile uses the provided bibliographic records and metrics without independently verifying database totals or claiming that individual studies establish clinical effectiveness.

Keywords

Antimicrobial resistance; colistin resistance; Enterobacteriaceae; CRISPR-Cas; oral microbiome; microbial pathogenesis; oral cancer; immunology; microbiology; bacterial infection.

Introduction

Antimicrobial resistance is a major research concern because resistant microorganisms can complicate infection management and limit treatment options. In parallel, investigations of the oral microbiome examine how microbial communities interact with host tissues and how particular organisms may be associated with inflammatory conditions and cancer. Gholizadeh’s listed publications address both areas, providing a basis for examining links between microbiological mechanisms and human health.[2]

Research Profile

The supplied records indicate a research portfolio spanning reviews, mechanistic investigations, and discussions of emerging antimicrobial technologies. Its interdisciplinary character is reflected in the relationship between microbial genetics, clinical microbiology, oral health, and infection research. The stated institutional affiliation is Ardabil University of Medical Sciences, Iran. A verified Scopus identifier and ORCID have not been supplied and should be added only after confirmation.

Research Contributions

One prominent theme is colistin resistance in Enterobacteriaceae, a subject relevant to the study of treatment options for difficult bacterial infections. Another is the possible relationship between oral microbial communities and oral cancers. The supplied publication list also includes work discussing Fusobacterium nucleatum in carcinogenesis and the potential use of CRISPR-Cas approaches to address antimicrobial resistance. These publications represent complementary perspectives on resistance mechanisms, microbial-host interactions, and emerging research strategies.[3]

  • Antibiotic resistance mechanisms and colistin resistance.
  • Oral microbiome research and potential disease associations.
  • CRISPR-Cas systems as a prospective research direction for antimicrobial resistance.

Publications

The following selected works are based on the bibliographic information supplied for this article. Citation counts can vary between databases and over time.

  1. Aghapour, Z., Gholizadeh, P., Ganbarov, K., et al. (2019). Molecular mechanisms related to colistin resistance in Enterobacteriaceae. Infection and Drug Resistance, 965–975.
  2. Gholizadeh, P., Eslami, H., Yousefi, M., et al. (2016). Role of oral microbiome on oral cancers, a review. Biomedicine & Pharmacotherapy, 84, 552–558.
  3. Gholizadeh, P., Eslami, H., & Kafil, H. S. (2017). Carcinogenesis mechanisms of Fusobacterium nucleatum. Biomedicine & Pharmacotherapy, 89, 918–925.
  4. Gholizadeh, P., Köse, Ş., Dao, S., et al. (2020). How CRISPR-Cas system could be used to combat antimicrobial resistance. Infection and Drug Resistance, 1111–1121.
  5. Gholizadeh, P., Pormohammad, A., Eslami, H., et al. (2017). Oral pathogenesis of Aggregatibacter actinomycetemcomitans. Microbial Pathogenesis, 113, 303–311.

Research Impact

The supplied profile figures report 110 documents, 4,556 citations, and an h-index of 37. These figures suggest a substantial publication and citation record if confirmed against the relevant database profile. They should be treated as user-provided values rather than independently verified statistics. Citation metrics measure particular aspects of scholarly attention and should be interpreted alongside research quality, methodological rigor, reproducibility, and practical relevance.

Award Suitability

The research themes and supplied publication record provide relevant material for consideration in an academic recognition process associated with the International Academic Excellence Awards. A fair assessment should consider verified publications, individual contributions, research quality, and documented impact. This profile does not establish that an award has been granted or that editorial board membership has been independently confirmed.

Conclusion

Pourya Gholizadeh’s selected publications cover important questions in antimicrobial resistance, oral microbiology, and microbial pathogenesis. Together, these topics illustrate connections between fundamental microbiological research and clinical challenges. Verification of bibliographic records, institutional affiliation, research metrics, and editorial role will strengthen the accuracy and reliability of this academic recognition profile.

References

  1. Google Scholar. (n.d.). Pourya Gholizadeh: author profile and publication records. https://scholar.google.com/citations?user=1XSHxVkAAAAJ&hl=en
  2. Gholizadeh, P., Eslami, H., Yousefi, M., et al. (2016). Role of oral microbiome on oral cancers, a review. Biomedicine & Pharmacotherapy, 84, 552–558. Publication record: Google Scholar record. DOI not independently verified.
  3. Aghapour, Z., Gholizadeh, P., Ganbarov, K., et al. (2019). Molecular mechanisms related to colistin resistance in Enterobacteriaceae. Infection and Drug Resistance, 965–975. Publication record: Google Scholar record. DOI not independently verified.
  4. Gholizadeh, P., Eslami, H., & Kafil, H. S. (2017). Carcinogenesis mechanisms of Fusobacterium nucleatum. Biomedicine & Pharmacotherapy, 89, 918–925. Publication record. DOI not independently verified.
  5. Gholizadeh, P., Köse, Ş., Dao, S., et al. (2020). How CRISPR-Cas system could be used to combat antimicrobial resistance. Infection and Drug Resistance, 1111–1121. Publication record. DOI not independently verified.
  6. Gholizadeh, P., Pormohammad, A., Eslami, H., et al. (2017). Oral pathogenesis of Aggregatibacter actinomycetemcomitans. Microbial Pathogenesis, 113, 303–311. Publication record. DOI not independently verified.
  7. International Academic Excellence Awards. (n.d.). Official award website. https://academicexcellenceawards.com/

hassan noorbazargan | Immunology | Best Researcher Award

Published on by Academic Excellence

Dr. hassan noorbazargan | Immunology | Best Researcher Award

Dr. hassan noorbazargan | Immunology | Carbon Technologies LLC | Oman 

Dr. Hassan Noorbazargan is a highly accomplished researcher specializing in biotechnology, immunology, and molecular diagnostics. He earned his Ph.D. in Medical Biotechnology from Shahid Beheshti University of Medical Sciences, Iran, where his doctoral work focused on the design and validation of advanced PCR assays for detecting HIV. His career reflects a strong combination of academic excellence and industrial expertise, spanning molecular diagnostics, vaccine production, recombinant protein development, and nanobiotechnology. Dr. Noorbazargan has held prominent roles at Carbon Technologies Co., ROJE Technologies, and the Pasteur Institute of Iran, where he contributed significantly to diagnostic assay development and vaccine quality control. His research contributions have led to impactful publications on nanocarriers, drug delivery, and novel therapeutic strategies for infectious diseases and cancer. Dedicated to advancing biotechnology and immunology, Dr. Noorbazargan continues to shape the scientific community with his innovative work, quality leadership, and pursuit of translational research.

Author Profiles

Orcid | Google Scholar

Education 

Dr. Hassan Noorbazargan pursued his Ph.D. in Biotechnology at Shahid Beheshti University of Medical Sciences, where he achieved a perfect GPA. His doctoral thesis focused on the design, development, and application of TaqMan real-time PCR for qualitative and quantitative detection of HIV, demonstrating his expertise in molecular diagnostics. Prior to this, he earned his M.Sc. in Microbiology from Islamic Azad University of Lahijan, where his thesis involved cloning and expression of the HCV core+1 protein in mammalian cells, highlighting his interest in virology and genetic engineering. He also completed his B.Sc. in Microbiology from the same university, where he developed a strong foundation in immunology, biochemistry, and cell biology. Through his academic journey, he undertook multiple research assistantships in microbiology and biotechnology labs, which helped refine his practical laboratory expertise. His educational achievements underline a consistent pursuit of excellence and research-driven learning.

Experience

Dr. Hassan Noorbazargan brings extensive experience in both academia and industry, specializing in diagnostics, vaccines, and nanobiotechnology. Currently serving as Senior Researcher & QC Head at Carbon Technologies Co., Muscat (2024–Present), he leads diagnostic kit validation for infectious diseases and ensures regulatory compliance. From 2019–2024, as Head of R&D at ROJE Technologies, he developed PCR assays for HIV, Hepatitis, and Influenza while managing technology transfer and GMP compliance. Earlier, he was a Senior R&D Specialist at Sinaclon, focusing on scaling molecular reagents and diagnostic kits. At the Pasteur Institute of Iran, he contributed as a Senior Scientist in BCG vaccine production and later as Scientific Advisor in vaccine development. His career also includes supervisory roles in clinical diagnostics and hands-on experience as a hospital lab technician. With a proven record in assay development, recombinant proteins, and nanocarriers, Dr. Noorbazargan continues to bridge research with translational healthcare solutions.

Awards and Honors

Throughout his career, Dr. Hassan Noorbazargan has earned recognition for his academic and research excellence in biotechnology and immunology. He successfully completed his Ph.D. with distinction at Shahid Beheshti University of Medical Sciences, where his groundbreaking work on HIV molecular detection positioned him as a leading scholar in molecular diagnostics. His innovative publications on nanocarriers, drug delivery systems, and novel therapeutic strategies for cancer and infectious diseases have been widely cited, reflecting their significant impact on the scientific community. He has also been acknowledged for his leadership in R&D roles, particularly in vaccine development and molecular assay validation, where his contributions directly influenced product innovation and clinical applications. In addition, Dr. Noorbazargan has participated in global training programs offered by WHO Academy, IAVI, Coursera, and edX, further strengthening his expertise. His ongoing pursuit of excellence and translational research has earned him recognition as a promising researcher in biotechnology and immunology.

Research Focus

Dr. Hassan Noorbazargan’s research is deeply rooted in immunology, nanobiotechnology, and molecular diagnostics. His focus lies in developing advanced diagnostic assays, nanocarrier-based drug delivery systems, and recombinant proteins for therapeutic and preventive medicine. A significant part of his work addresses infectious diseases such as HIV, Hepatitis, and COVID-19, where he has designed and validated cutting-edge PCR and ELISA-based assays for accurate detection. Beyond infectious diseases, his research explores innovative cancer therapies using niosomes, nanogels, and metal-organic frameworks for targeted and site-specific drug delivery. His publications highlight enhanced antibacterial, anticancer, and anti-metastatic strategies through engineered nanostructures, offering breakthroughs in precision medicine. He also contributes to vaccine research, optimizing immunogenicity assays and quality systems to improve vaccine safety and efficacy. By integrating molecular biology, immunology, and biotechnology, Dr. Noorbazargan’s research strengthens the bridge between laboratory innovation and clinical application, ultimately advancing global healthcare outcomes.

Publications

  • Narrative review on traditional medicine options for COVID-19 treatment.

  • Curcumin-loaded niosome nanocarriers for breast cancer therapy.

  • Ciprofloxacin-encapsulated niosomes for enhanced antibacterial activity.

  • Doxycycline-loaded niosomal formulation for prostate cancer treatment.

  • Niosome-loaded selenium nanoparticles for antibacterial and anticancer activities.

  • Folate-conjugated nanogels encapsulating oxaliplatin for colorectal cancer therapy.

  • Silver nanoparticles from Juniperus chinensis with anticancer properties.

  • Cefazolin-encapsulated UIO-66-NH2 nanoparticles against resistant S. aureus.

  • Folate-targeted curcumin-loaded niosomes for breast cancer treatment.

  • Biogenic AgNPs from Artemisia oliveriana for lung cancer therapy.

  • Engineered UIO-66 MOF delivering curcumin for breast cancer cells.

  • Super magnetic niosomal nanocarriers for breast cancer therapy.

Conclusion

Dr. Hassan Noorbazargan is a promising scientist whose research combines immunology, molecular diagnostics, and nanomedicine to address critical challenges in infectious diseases and cancer. With a balance of academic achievements, industrial expertise, and impactful publications, he stands as a strong candidate for global recognition in biomedical research.